BACKGROUND AND OBJECTIVES: This study evaluated predictors for patient and renal survival in patients with ANCA-associated vasculitis (AAV) with and without renal involvement. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: There were 273 consecutive AAV patients from January 1990 until December 2007 who were followed until death, loss to follow-up, or December 2010. Based on organ involvement, patients were divided into renal (n=212) and nonrenal groups (n=61). The primary end point was ESRD requiring renal replacement therapy (RRT) or renal transplantation or death. RESULTS: Patient survival was significantly better in the nonrenal group compared with the renal group (hazard ratio, 0.55; 95% confidence interval, 0.33 to 0.92; P=0.02). In the renal group, renal survival was significantly worse in MPO-ANCA-positive patients (n=65) compared with PR3-ANCA-positive patients (n=138) (hazard ratio, 2.1; 95% confidence interval, 1.11 to 3.8; P=0.01). Of 48 patients who needed RRT at diagnosis, 11 patients (23%) died within 6 months and 14 patients (29%) did not regain renal function. Of all 23 patients who regained renal function after RRT, 7 patients (30%) were temporarily dialysis independent and needed dialysis later (range, 13-63 months). Five patients had a renal relapse in the 6 months before restart of RRT. Of all 203 PR3-ANCA-positive and MPO-ANCA-positive patients with renal involvement, 12 patients (6%) developed ESRD during follow-up. These patients were classified as CKD stage 4 or 5 after initial treatment and eight patients had a renal relapse before becoming dialysis dependent. CONCLUSIONS: AAV patients with renal involvement who needed RRT had the worst survival probability. In multivariate analysis, the only major determinants for long-term renal survival were renal function at 6 months and renal relapses.
BACKGROUND AND OBJECTIVES: This study evaluated predictors for patient and renal survival in patients with ANCA-associated vasculitis (AAV) with and without renal involvement. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: There were 273 consecutive AAV patients from January 1990 until December 2007 who were followed until death, loss to follow-up, or December 2010. Based on organ involvement, patients were divided into renal (n=212) and nonrenal groups (n=61). The primary end point was ESRD requiring renal replacement therapy (RRT) or renal transplantation or death. RESULTS:Patient survival was significantly better in the nonrenal group compared with the renal group (hazard ratio, 0.55; 95% confidence interval, 0.33 to 0.92; P=0.02). In the renal group, renal survival was significantly worse in MPO-ANCA-positive patients (n=65) compared with PR3-ANCA-positive patients (n=138) (hazard ratio, 2.1; 95% confidence interval, 1.11 to 3.8; P=0.01). Of 48 patients who needed RRT at diagnosis, 11 patients (23%) died within 6 months and 14 patients (29%) did not regain renal function. Of all 23 patients who regained renal function after RRT, 7 patients (30%) were temporarily dialysis independent and needed dialysis later (range, 13-63 months). Five patients had a renal relapse in the 6 months before restart of RRT. Of all 203 PR3-ANCA-positive and MPO-ANCA-positive patients with renal involvement, 12 patients (6%) developed ESRD during follow-up. These patients were classified as CKD stage 4 or 5 after initial treatment and eight patients had a renal relapse before becoming dialysis dependent. CONCLUSIONS: AAV patients with renal involvement who needed RRT had the worst survival probability. In multivariate analysis, the only major determinants for long-term renal survival were renal function at 6 months and renal relapses.
Authors: Zuzana Rihova; Eva Jancova; Miroslav Merta; Romana Rysava; Jana Reiterova; Jiri Zabka; Vladimir Tesar Journal: Kidney Blood Press Res Date: 2005-05-20 Impact factor: 2.687
Authors: Herbert A Hauer; Ingeborg M Bajema; Hans C Van Houwelingen; Franco Ferrario; Laure-Hélène Noël; Rüdiger Waldherr; David R W Jayne; Niels Rasmussen; Jan A Bruijn; E Christiaan Hagen Journal: Kidney Int Date: 2002-11 Impact factor: 10.612
Authors: C F Franssen; C A Stegeman; C G Kallenberg; R O Gans; P E De Jong; S J Hoorntje; J W Tervaert Journal: Kidney Int Date: 2000-06 Impact factor: 10.612
Authors: Anthony D Booth; Mike K Almond; Aine Burns; Peter Ellis; Gill Gaskin; Guy H Neild; Martin Plaisance; Charles D Pusey; David R W Jayne Journal: Am J Kidney Dis Date: 2003-04 Impact factor: 8.860
Authors: C F Franssen; C A Stegeman; W W Oost-Kort; C G Kallenberg; P C Limburg; A Tiebosch; P E De Jong; J W Tervaert Journal: J Am Soc Nephrol Date: 1998-10 Impact factor: 10.121
Authors: Paul A Lyons; Tim F Rayner; Sapna Trivedi; Julia U Holle; Richard A Watts; David R W Jayne; Bo Baslund; Paul Brenchley; Annette Bruchfeld; Afzal N Chaudhry; Jan Willem Cohen Tervaert; Panos Deloukas; Conleth Feighery; Wolfgang L Gross; Loic Guillevin; Iva Gunnarsson; Lorraine Harper; Zdenka Hrušková; Mark A Little; Davide Martorana; Thomas Neumann; Sophie Ohlsson; Sandosh Padmanabhan; Charles D Pusey; Alan D Salama; Jan-Stephan F Sanders; Caroline O Savage; Mårten Segelmark; Coen A Stegeman; Vladimir Tesař; Augusto Vaglio; Stefan Wieczorek; Benjamin Wilde; Jochen Zwerina; Andrew J Rees; David G Clayton; Kenneth G C Smith Journal: N Engl J Med Date: 2012-07-19 Impact factor: 91.245
Authors: Marta Casal Moura; Maria V Irazabal; Alfonso Eirin; Ladan Zand; Sanjeev Sethi; Bijan J Borah; Jeffrey L Winters; James P Moriarty; Rodrigo Cartin-Ceba; Alvise Berti; Misbah Baqir; Gwen E Thompson; Ashima Makol; Kenneth J Warrington; Viengneesee Thao; Ulrich Specks; Fernando C Fervenza Journal: J Am Soc Nephrol Date: 2020-08-21 Impact factor: 10.121